Atazanavir / cobicistat

Eletriptan

Contraindicated.

No pharmaceutical opinion available for this interaction.

Mechanism

Atazanavir / cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Eletriptan.

Atazanavir / cobicistat

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Eletriptan

Pharmacodynamic effects

Possible increase of adverse effects.

Recommendations

Contraindicated. Use alternative.

In patients already being treated with this combination and tolerating it, if deemed appropriate, keep actual treatment and exercise close monitoring of adverse effects.

Alternative solution(s)

Frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex) or zolmitriptan (Zomig)

Monitor

Migraine symptoms and eletriptan adverse effects : chest tightness, vasoconstriction, hypertension, nausea, drowsiness and serotonin syndrome.

Tests

Pharmacokinetic parameters

Comment

Ref #3122 : During a clinical trial, it was found that eletriptan Cmax and AUC were increased by about 3 to 6-fold respectively when this agent was administered with ketoconazole, and that eletriptan half-life stretched from 5 to 8 hours and Tmax from 2.8 to 5.4 hours.

Comment
Reference
  • 3122
    Eletriptan (Relpax), Pfizer, Québec, Canada, 26 novembre 2013.